unresectable or recurrent gastric cancer
Conditions
Interventions
5weeks/cycle, 2cycles 1mg of VEGFR1 petitide and 1mg of VEGFR2 peptide inject under the skin week by week.
Sponsors
Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery
Institute of Medical Science , University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The inclusion criteria were as follows 1)gastric cancer 2)unresectable or reccurent gastric cancer 3)paformance status (ECOG) of 0-1 4)major organ function preserved 5)the case should survival for at least 3 months 6)there is at least one estimative lesion 7)over 4week from previously treatment 8)oral intake possible
Exclusion criteria
Exclusion criteria: The exclusion criteria were as follows 1)patients with serious concomitant disease 2)pregnancy 3)lactating 4)hope pregnancy 5)uncontrolled infection 6)cannot stopped steroids or immunosuppressing drug 7)simultaneous or metachronous double cancers 8)unhealed external injury 9)patients with ileus and interstitial lung disease 10)the cases whom the doctors define as inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety and time to progression | — |
Secondary
| Measure | Time frame |
|---|---|
| immunological evaluation, anticancer efficacy, accomplishment rate, 1 & 2 years survival rate, median survival time | — |
Countries
Japan
Contacts
Public ContactYoshiyuki Fuijwara
Osaka University, Graduate School of Medicine Gastroenterological Surgery
Outcome results
None listed